metoprolol succinate / Generic mfg. - LARVOL DELTA

Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: University of Michigan

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

BRASH Syndrome: A Rare but Critical Cause of Bradycardia and Shock in the Elderly (SCCM 2026) - "Home medications included metoprolol succinate and diltiazem...Hyperkalemia was treated with IV calcium gluconate, insulin with dextrose, albuterol, and furosemide...This distinction can guide targeted management. Conclusions were developed with AI assistance."

Clinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Hypotension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

LONG-TERM MANAGEMENT OF STANDARD-OF-CARE THERAPY IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TREATED WITH MAVACAMTEN (ACC 2026) - "To evaluate changes in AVNB exposure, beta blocker total daily doses were converted to metoprolol succinate equivalents. Treatment with mavacamten enabled decreases in background AVNB therapy in patients with symptomatic oHCM."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

TRIPLE THREAT: A CASE OF ANGIOEDEMA AND MYOPERICARDITIS COMPLICATING SYSTEMIC LUPUS ERYTHEMATOSUS (ACC 2026) - "She was initiated on dapagliflozin and metoprolol succinate, with sacubitril-valsartan initially avoided due to angioedema history. She was also initiated on hydroxychloroquine, mycophenolate, and high-dose steroids...Symptoms improved and she was discharged on full GDMT, tapered prednisone, and close follow up... Angioedema can be mast cell-mediated or kinin-mediated. Our patient likely developed acquired angioedema due to her C1q deficient SLE given no family history. Given that her SLE also led to myopericarditis with newly diagnosed heart failure, the decision to initiate an ACE/ARB/ARNi was unique in light of her recent angioedema."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

REVERSIBLE SEVERE DILATED CARDIOMYOPATHY IN A YOUNG ADULT WITH CONGENITAL HEART BLOCK FOLLOWING DIAGNOSIS AND TREATMENT OF HASHIMOTO'S THYROIDITIS (ACC 2026) - "Achieved normalization of free thyroxine with levothyroxine. Guideline-directed medical therapy (GDMT) limited by renal failure, initiated on hydralazine, isosorbide dinitrate, and metoprolol succinate... Recognition of autoimmune thyroid disease as a contributor to cardiac dysfunction warrants further investigation and may inform future guidelines on cardiovascular screening in patients with autoimmune thyroiditis. Early diagnosis and targeted management of reversible causes of DCM, including thyroid hormone replacement and optimization of GDMT are essential to improving outcomes in this population."

Clinical • Amyloidosis • Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Developmental Disorders • Endocrine Disorders • Fibrosis • Heart Failure • Immunology • Inflammation • Renal Disease • Septic Shock

COMPARISON OF BETA BLOCKER ADHERENCE BETWEEN ONCE VS TWICE A DAY DOSING REGIMENS IN PATIENTS HEART FAILURE WITH REDUCED EJECTION FRACTION (ACC 2026) - " Among 2,699 patients (mean age 66 years, 35% female, 38% White), 1952 (72%) were discharged on twice daily BBs (88% carvedilol, 9% bisoprolol, and 3% metoprolol succinate). Once versus twice daily BB was not associated with a significant difference in achieving PDC ≥80% at one year. These findings suggest that dosing frequency alone may not significantly influence GDMT BB adherence and other factors such as BB selectivity may play a more prominent role."

Adherence • Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

HEART FAILURE WITH IMPROVED EJECTION FRACTION IN A PATIENT WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ACC 2026) - "However, the patient was able to tolerate guideline-directed medical therapy with metoprolol succinate 25 mg, sacubitril-valsartan 24/26 mg, spironolactone 12.5 mg, isosorbide dinitrate/hydralazine 20/37.5 mg, as well as tafamidis and vutrisiran. Future studies should clarify the role of contemporary GDMT and identify the subset of cardiac amyloidosis patients with reduced LV function who may derive clinical benefit."

Clinical • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease • Solid Organ Transplantation

NAVIGATING NSTEMI IN THE FIRST TRIMESTER OF PREGNANCY: FIT-GUIDED CONSERVATIVE MANAGEMENT IN A LOW-RISK PATIENT (ACC 2026) - "She remained stable for the duration of her hospitalization and was discharged with prophylactic enoxaparin, metoprolol succinate and aspirin with outpatient follow up. NSTEMI in the first trimester is exceedingly rare. This case underscores the importance of individualized care that prioritizes maternal and fetal safety and minimizes procedural risks in stable pregnant patients who present with NSTEMI. The patient is currently still pregnant and doing well."

Clinical • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Heart Failure • Hematological Disorders • Hypertension • Myocardial Infarction • Thrombosis

A BRIDGE TO RECOVERY: OPTIMIZING GUIDELINE DIRECTED MEDICAL THERAPY IN ADVANCED HFREF WITH BETA BLOCKER AND DOBUTAMINE SYNERGISTICALLY (ACC 2026) - "After stabilization, she was discharged on dobutamine 5 mcg/kg/min and metoprolol succinate 25 mg daily. This case shows the feasibility of combining beta blockers with dobutamine to optimize GDMT in advanced HFrEF, resulting in sustained recovery and successful addition of GDMT. The strategy enabled transition from inotrope dependence to outpatient stability and long-term GDMT maintenance"

Metastases • Cardiovascular • Congestive Heart Failure • Heart Failure

REASSESSING β-BLOCKERS IN HFPEF: PRESCRIBING PATTERNS AND OUTCOMES IN THE CARDIOMETABOLIC CENTER ALLIANCE REGISTRY (ACC 2026) - " Among 620 patients, 72.8% were on BBs at index: 3.3% low-, 80.0% moderate- and 16.7% high-dose therapy that exceeded recommended HF initiation (e.g., metoprolol succinate 25 mg)... In this multisite HFpEF cohort, nearly 75% of patients received BB therapy, most at moderate or high doses, despite limited HFpEF-specific benefit, few hemodynamic indications and frequent continuation after isolated ischemic events. These patterns reflect a lack of tailored prescribing and highlight opportunities to de-escalate or discontinue therapy in selected patients while emphasizing lifestyle and alternative treatments."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Myocardial Infarction

A Novel Case of Hypertrophic Obstructive Cardiomyopathy in an Adult Patient with Distal Partial Trisomy 15q (ACMG 2026) - "Treatment and Management Due to findings consistent with heart failure with preserved ejection fraction, the patient was started on empagliflozin, sacubitril-valsartan, and twice daily furosemide as needed for edema or shortness of breath. Metoprolol succinate was started for HOCM...He is scheduled to receive a repeat cMRI to further evaluate the LVEF before mavacamten initiation...This case may expand on known phenotypes of distal partial trisomy 15q with a novel presentation of HOCM. Further research is needed to better describe the known cardiac phenotype of distal partial trisomy 15q."

Clinical • Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Developmental Disorders • Epilepsy • Heart Failure • Hypertrophic Cardiomyopathy • Mental Retardation • Movement Disorders • Obstructive Hypertrophic Cardiomyopathy • Pulmonary Disease

TRENDS IN GUIDELINE-DIRECTED MEDICAL THERAPY AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (ISPOR 2026) - "GDMT consisted of an evidence-based β‑blocker (carvedilol/metoprolol succinate/bisoprolol); ACE inhibitor, ARB, or ARNI; MRA; and SGLT2i. Prescribing and dispensing of GDMT in patients with HFrEF improved during 2020-2024 but remained underutilized. Similar findings were observed with rapid initiation of GDMT. Greater effort is needed to ensure timely initiation of these therapies."

Clinical • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Obesity

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF) (clinicaltrials.gov) - P4 | N=240 | Enrolling by invitation | Sponsor: Weill Medical College of Cornell University | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. (PubMed, J Am Coll Cardiol) - P3 | "Aficamten improved the health status of patients with symptomatic oHCM significantly more than did metoprolol, highlighting its potential as an effective initial therapeutic option. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (MAPLE-HCM; NCT05767346)."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Weak Pulse at Yang and Wiry Pulse at Yin Theory (clinicaltrials.gov) - P=N/A | N=70 | Completed | Sponsor: Xikun Li

New trial • Cardiovascular • Coronary Artery Disease • Heart Failure

Towards sustainable pharmaceutical QC: micellar-UPLC strategy for concomitant analysis of a cardiovascular polypill with aniline and salicylic acid impurities. (PubMed, Sci Rep) - "This combination includes four active ingredients: aspirin (ASR), atorvastatin calcium (ATC), metoprolol succinate (MES), and ramipril (RAP). Whiteness and greenness appraisals were performed, affirming the applied approach's friendliness to the environment. The priority of this UPLC approach over the published LC ones is due to using a micellar moving phase, making it more eco-friendly to the environment, and the determination of the aforementioned drugs even in the presence of aniline (toxic impurity) and salicylic acid."

Journal • Cardiovascular • Dyslipidemia • Hypertension • Myocardial Infarction

Statin-Associated Headache: A Rare and Underrecognized Clinical Presentation: A Case Report. (PubMed, Reports (MDPI)) - "In this case, the patient was taking metoprolol succinate, lisinopril, simvastatin, clopidogrel, and tamsulosin. Clinicians should remain vigilant about the possibility of statin-induced headache, even in long-term users. Early recognition can prevent unnecessary diagnostic investigations, expedite symptom resolution, and support optimal management of both cardiovascular risk and treatment-related adverse effects."

Journal • Cardiovascular • Musculoskeletal Pain • Pain

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF) (clinicaltrials.gov) - P4 | N=240 | Not yet recruiting | Sponsor: Weill Medical College of Cornell University

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. (PubMed, J Am Coll Cardiol) - P3 | "In patients with symptomatic oHCM, aficamten monotherapy led to superior and rapid treatment benefits across several clinically relevant outcome measures of disease burden compared with metoprolol. These observations support the emerging role of aficamten as monotherapy for oHCM. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM [MAPLE-HCM]; NCT05767346)."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Comparative Impact of Metoprolol Succinate and Carvedilol on Optimization of Guideline-Directed Therapy in Heart Failure With Reduced Ejection Fraction (ASHP 2025) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

Comparison of Metoprolol Succinate and Carvedilol and Implementing all 4 pillars of Guideline-Directed Medication Therapy (GDMT) (ASHP 2025) - No abstract available

Babesiosis masquerading as ITP in a patient with CLL (ASH 2025) - "Patient's home medications included only ramipril and metoprolol succinate...Patient was started on atovaquone and azithromycin...And patient was diagnosed with Babesiosis. This case highlights how Babesiosis can masquerade as ITP and present as severe thrombocytopenia without any symptoms suggestive of infection."

Clinical • Cardiovascular • Chronic Lymphocytic Leukemia • Coronary Artery Disease • Dyslipidemia • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Thrombocytopenia • HP

Greenness Assessment and Stability-Indicating Hptlc Method for The Concurrent Analysis of Empagliflozin and Metoprolol Succinate in A Novel Combined Oral Formulation. (PubMed, Drug Dev Ind Pharm) - "The method demonstrated precision in both intraday (EMP-8738.68 ± 80.86 and METO- 4510.93 ± 27.61) and interday (EMP-8744.97 ± 131.91 and MET0-4492.87 ± 32.53) analyses and repeatability, with the %RSD of the peak area remaining below 2%. The stressed degradation conditions were optimized to induce degradation ranging from 5% to 20%.Conclusion- The validated HPTLC method is precise, accurate, and stability-indicating, making it suitable for routine quality control and stability testing of EMP-METO bilayer tablets."

Journal

The Proof is in the Pillbox: An Elusive Case of Cardiomyopathy (AHA 2025) - "A 63-year-old female with mixed connective tissue disease on long-term immunosuppression (prednisone, azathioprine, hydroxychloroquine (HCQ)) was referred to a tertiary care center for evaluation of progressive dyspnea and exertional chest discomfort...Catheterization revealed severe pulmonary hypertension and elevated filling pressures, without significant coronary disease.Medical treatment included empagliflozin (discontinued due to urosepsis), bumetanide, spironolactone, and metoprolol succinate...Multimodal imaging and biopsy are crucial for diagnosis. Early recognition is essential to prevent irreversible myocardial damage and improve long-term outcomes."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Ventricular Tachycardia

A Polypill Strategy for Heart Failure with Reduced Ejection Fraction: The POLY-HF Trial (AHA 2025) - P2 | "Polypill strategies have been trialed for prevention of atherosclerotic conditions but not in HFrEF.Hypothesis: We hypothesized that an HFrEF polypill containing metoprolol succinate, spironolactone, and empagliflozin would improve left ventricular ejection fraction (LVEF) compared with usual care in patients. POLY-HF is a two-center, open-label RCT conducted primarily within a safety-net healthcare system in Dallas, TX (NCT04633005). POLY-HF enrolled a diverse population with high burden of adverse SDOH and poor medication adherence. Database lock is anticipated in October 2025, and complete results will be presented at the meeting. This trial will provide the first randomized evidence for polypill effectiveness on biologic and clinical outcomes in HFrEF among underrepresented populations."

Late-breaking abstract • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Heart Failure